Syed Ali, MD
Nephrology · Atlantis, FLNPI 1679544704
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,270 of the $3,746 with a category attached, or 87.3%. Janssen Scientific Affairs, LLC accounts for 87.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $3,270 and has fallen 95.5% since, to $147 in 2025.
Across 18 payments — averaging $208.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$3K
- Boston Scientific$147
- AstraZeneca$86
- Merck$60
- Mallinckrodt Enterprises LLC$34
- Vifor Pharma, Inc.$30
- plus $119 from 7 others
What the payments were for
- Consulting fees$3,27087%
- Food & beverage$47613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $3,270 |
| Boston Scientific | 1 | $147 |
| AstraZeneca | 1 | $86 |
| Merck | 4 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $30 |
| Amgen | 1 | $23 |
| Cook Medical LLC | 1 | $22 |
| Insmed, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Pfizer | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECVAYLI$3,270
- WATCHMAN FLX$147
How this compares
$3,746 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 14 | $594 |
| Calcium Acetate | 12 | $351 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Atlantis
- Jose ArrascueAtlantis$39K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.